Ovarian carcinoma

This phase 1 trial tests an experimental therapy called AB-1015 in people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. AB-1015 uses a patient's own T cells, which are genetically engineered to recognize and…

This study tests a new drug called SKB264 in people with advanced solid tumors that have not responded to standard therapies. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The trial includes over 1,400 participants with various …

This early-phase study is testing whether taking a daily 325 mg aspirin alongside standard chemotherapy can reduce immune-suppressing cells in ovarian, fallopian tube, or peritoneal tumors. About 100 women will take either aspirin or a placebo for up to 5 cycles of chemo. The goa…

Researchers are testing an experimental antibody called ONC-392 in people with advanced solid tumors, including non-small cell lung cancer and melanoma. The trial gives ONC-392 alone or with pembrolizumab, an approved immunotherapy, to see what doses are safe and how the body pro…

This study tested a combination of two drugs, veliparib and topotecan, in 88 patients with solid tumors or ovarian cancer that returned after initial treatment. The goal was to find the safest dose and see how well the drugs shrink tumors. While the treatment aims to control the …

This study tests an experimental drug called TransCon IL-2 β/γ, which aims to boost the immune system to fight cancer. It is given alone or with other treatments like pembrolizumab (Keytruda) or chemotherapy. The trial includes 320 adults with advanced solid tumors that have not …

This study tests whether adding an experimental drug (AZD1775) to standard chemotherapy (gemcitabine) helps women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatments. About 124 women will be randomly assigned to receive eith…

This study tests a new drug called Rina-S against standard chemotherapy for people with ovarian cancer that has stopped responding to platinum-based treatments. About 530 participants will be randomly assigned to receive either Rina-S or one of four approved chemo drugs. The goal…

This early-phase study tests a new drug called M9466, a PARP1 inhibitor, alone or combined with other drugs in 60 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and how the body processes the drug. Researchers …

This phase 2 trial tests whether adding an experimental drug called M6620 (berzosertib) to standard gemcitabine chemotherapy helps women with ovarian, fallopian tube, or primary peritoneal cancer that came back after platinum-based treatment. About 70 participants will receive ei…

This early-phase study tests the safety and best dose of a drug called veliparib when given with two chemotherapy drugs (carboplatin and paclitaxel) in people with advanced solid tumors that have spread or can't be removed. It includes patients who also have liver or kidney probl…

This early-phase trial tests two different drug combinations—olaparib plus vistusertib, or olaparib plus capivasertib—in people with recurrent endometrial, triple-negative breast, ovarian, primary peritoneal, or fallopian tube cancer. The main goal is to find the safest dose and …

This early-stage trial tests FF-10850, a liposome-wrapped version of the chemotherapy drug topotecan, in 96 adults with advanced solid tumors like ovarian, cervical, and Merkel cell carcinoma. The main goals are to find the safest dose and understand side effects. Researchers hop…

This early-phase trial is testing whether adding the targeted drug ipatasertib to standard chemotherapy (paclitaxel and carboplatin) is safe and effective for women with advanced ovarian cancer. The study involves 25 participants with stage III or IV disease. The goal is to find …

This study tests whether adding immunotherapy (atezolizumab) and/or a blood vessel blocker (bevacizumab) to standard chemo (pegylated liposomal doxorubicin) works better for ovarian cancer that has stopped responding to platinum drugs. About 444 women with recurrent ovarian, fall…

This phase 3 trial tests two different chemotherapy regimens, with or without the targeted drug bevacizumab, as first treatment for a rare type of ovarian or fallopian tube cancer called mucinous epithelial cancer. About 50 patients with newly diagnosed or recurrent cancer will b…

This study tests whether using a fluorescent dye and special camera during ovarian cancer surgery can help surgeons see blood flow in the bowel and reduce the risk of leaks after reconnecting it. About 310 women with ovarian cancer who need bowel surgery will be randomly assigned…

This phase II trial tests whether adding the immunotherapy tremelimumab to the PARP inhibitor olaparib works better than olaparib alone for women with platinum-sensitive recurrent ovarian, fallopian tube, or peritoneal cancer. About 61 participants will receive either olaparib al…

This early-phase trial tests a new approach for recurrent ovarian, fallopian tube, or peritoneal cancer. Doctors take stem cells from the patient's fat tissue, infect them with a modified measles virus, and inject them into the abdomen. The idea is that the stem cells will delive…

This phase II trial is testing whether combining two targeted drugs, palbociclib and binimetinib, can help people with cancers that have RAS mutations. The study includes patients with pancreatic cancer, ovarian cancer, and other solid tumors. Researchers want to see if the drug …

This early-phase study tests a combination of two drugs, niraparib and dostarlimab, in 18 adults with BRCA-mutated breast, pancreas, or ovary cancer that has spread or cannot be surgically removed. Niraparib blocks a DNA repair protein in cancer cells, while dostarlimab helps the…

This phase 2 trial is testing the drug talazoparib in people with advanced solid tumors that have specific mutations in DNA repair genes. Talazoparib works by blocking a protein called PARP, which cancer cells use to fix their damaged DNA, leading to cancer cell death. The study …

This early-phase trial tests a new drug called ZEN003694, which blocks certain enzymes that help cancer grow, combined with two immunotherapy drugs (nivolumab and ipilimumab) that boost the immune system to attack cancer. The study includes 66 adults with advanced solid tumors, i…

This early-phase trial is testing whether giving heated chemotherapy directly into the abdomen during surgery is safe for people with advanced ovarian, fallopian tube, or peritoneal cancer. Participants will receive standard chemotherapy before surgery, and then either heated che…

This early-stage study is testing a new drug, AB801, alone or with other treatments, in about 91 people with advanced cancers (like lung, colon, or breast cancer) that have not responded to standard therapies. The main goal is to check the drug's safety and find the best dose for…

This study tests a new treatment called ADP-A2M4CD8, made from a patient's own immune cells, for ovarian cancer that has returned. It is given alone or with another drug (nivolumab) to see if it can shrink tumors. About 66 people with a specific genetic marker (HLA-A*02 and MAGE-…

This early trial is testing whether the drug olaparib can shrink tumors in people with newly diagnosed BRCA-mutant ovarian, fallopian tube, or peritoneal cancer before they have surgery. Fifteen participants will receive olaparib for two cycles, then undergo standard chemotherapy…

This phase II trial tests whether the drug bevacizumab (Avastin) can help control ovarian, fallopian tube, or primary peritoneal cancer that is still present after initial treatment. About 35 women whose cancer was found during a second-look surgery will receive bevacizumab every…

This early-phase study tests a new oral drug, ATV-1601, in people with advanced solid tumors or certain breast cancers that have a specific AKT1 E17K mutation. The main goals are to check safety, find the right dose, and see how the drug moves through the body. About 134 adults w…

This study tests whether combining three drugs (durvalumab, olaparib, and cediranib) works better than standard chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatment. About 120 women will receive one of s…

This study looks at whether adding Juice Plus+ supplements to the diet helps ovarian cancer patients who are in remission. About 75 participants will either take the supplements plus get dietary counseling, or receive counseling alone. Researchers will measure changes in blood ma…

This phase 2 trial tests whether adding olaparib to selumetinib works better than selumetinib alone for women with recurrent or persistent ovarian or endometrial cancers that have a RAS pathway mutation. Selumetinib blocks enzymes that help cancer grow, while olaparib stops cance…

This early-phase trial tests an experimental drug called BAY 1895344 combined with standard chemotherapy (cisplatin, with or without gemcitabine) in people with advanced solid tumors, especially urothelial cancer. The goal is to find the best dose and see how safe the combination…

This phase 1 trial tests a combination of the chemotherapy drug gemcitabine and the targeted drug elimusertib in people with advanced pancreatic, ovarian, or other solid tumors that have spread. The goal is to find the safest dose and see whether the combination can shrink or sta…

This phase 2 study tests whether combining two oral drugs, olaparib and cediranib, can help control recurrent ovarian, peritoneal, or fallopian tube cancer. About 70 participants with high-grade serous or endometrioid cancers are enrolled. The goal is to see if the combination ca…

This early-phase trial tests whether adding an experimental drug called berzosertib to standard chemotherapy (carboplatin and gemcitabine) can better treat ovarian, peritoneal, or fallopian tube cancer that has returned and spread. The study involves 35 adults with platinum-sensi…

This study tests whether olaparib (a targeted drug) alone or combined with cediranib (which blocks tumor blood vessels) works better than standard platinum chemo for women whose ovarian, fallopian tube, or peritoneal cancer has returned after initial treatment. About 579 particip…

This early-phase trial tests a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system fight cancer) and ziv-aflibercept (which cuts off blood supply to tumors)—in people with advanced solid tumors like melanoma, colorectal, ovarian, and kidney cance…

This study tests a combination of three drugs—ALX148, liposomal doxorubicin, and pembrolizumab—in people with recurrent ovarian cancer that no longer responds to platinum-based chemotherapy. The goal is to see if blocking the CD47 protein on cancer cells can boost the immune syst…

This early-phase trial tests a new drug called peposertib combined with a standard chemotherapy (PLD) in people with ovarian or related cancers that have stopped responding to platinum-based treatment. The main goal is to find the safest dose and understand side effects. About 54…

This Phase II trial tests a drug called PLX038 in 43 people with ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum-based chemotherapy. The drug works by blocking enzymes that help cancer cells grow. Researchers will check if it shrinks tumors a…

This study tests a drug called adavosertib, given alone or with olaparib, in women with ovarian, fallopian tube, or peritoneal cancer that has returned and stopped responding to PARP inhibitors. The goal is to see if these drugs can shrink tumors or stop them from growing. About …

This phase 2 trial tests whether combining a vaccine that targets the p53 protein (p53MVA) with the immunotherapy drug pembrolizumab can shrink tumors in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer that has stopped responding to platinum-based ch…

This trial investigates a new type of immunotherapy for people with advanced cancers that carry a specific marker called NY-ESO-1. Researchers take a patient's own T cells, modify them in the lab to better recognize and attack cancer cells, and then infuse them back. The study al…

This trial tests whether adding a personalized vaccine and immune-boosting drugs to standard chemotherapy can help the body fight advanced ovarian cancer more effectively. Participants receive chemotherapy directly into the abdomen along with oral medication and injections of a v…

This phase 2 trial tests whether combining bevacizumab (a drug that blocks blood vessel growth) with anetumab ravtansine (a targeted therapy) works better than standard paclitaxel chemotherapy for women with ovarian, fallopian tube, or primary peritoneal cancer that no longer res…

This Phase 3 trial tests whether adding durvalumab (an immunotherapy) and olaparib (a targeted drug) to standard chemotherapy and bevacizumab can help people with newly diagnosed advanced ovarian cancer live longer without their cancer growing. About 1,400 participants are involv…

This study tests whether combining two drugs, cediranib and olaparib, works better than either drug alone or standard chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that no longer responds to platinum-based chemo. About 582 women will be randomly assign…

This early-stage trial tests a new drug called remzistotug, alone or with other cancer drugs, in 152 people with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. It is not yet known if the drug will sh…

This phase IV trial tests whether the drugs olaparib and bevacizumab, taken together after initial chemotherapy, can help prevent ovarian cancer from coming back in women with a specific genetic marker (HRD-positive). About 190 participants who have already responded to first-lin…

This early-phase trial tests a new treatment called IVS-3001, which uses a patient's own immune cells (T cells) engineered to target a protein called HLA-G found on some solid tumors. The study involves 31 adults with advanced solid tumors that have not responded to standard trea…

This trial tests an experimental drug called TRK-950 in combination with several standard anti-cancer treatments for people with advanced solid tumors, including colorectal, bladder, ovarian, and other cancers. The main goal is to find safe doses and understand side effects. Part…

This early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…

This phase II trial is testing the drug tazemetostat in 62 patients whose ovarian or endometrial cancer has returned after prior treatment. The goal is to see if tazemetostat can shrink tumors or stop them from growing. Participants will receive the drug and be monitored for resp…

This early-phase trial tests several new drug combinations in people with advanced solid tumors (like stomach, ovarian, or liver cancer) that have spread and stopped responding to standard treatments. The goal is to find the safest dose and see if the drugs can help control the c…

This early-phase study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy can help control advanced ovarian, fallopian tube, or primary peritoneal cancer. About 18 people with stage III or IV cancer will receive the combination. The main goal is to me…

This study was designed to test whether a new drug called M4344, combined with the PARP inhibitor niraparib, could be safe and effective for women with recurrent ovarian cancer that had stopped responding to PARP inhibitors. The plan was to enroll women with advanced ovarian, pri…

This Phase 3 trial is testing whether adding mirvetuximab soravtansine (a drug that targets a protein called FRα on cancer cells) to standard bevacizumab maintenance therapy can delay cancer progression in women with recurrent ovarian, fallopian tube, or peritoneal cancer. The st…

This phase 2 trial tests a new drug called SKB264, given by IV every two weeks, in 20 women with recurrent ovarian epithelial cancer. It also looks at how the antibiotic clarithromycin affects SKB264 levels in the body. The main goals are to see if the drug shrinks tumors and to …

This study tests whether a two-drug combination can help the immune system attack ovarian cancer that has returned after standard treatments. The drugs are E7777, which removes certain immune cells that block the body's defenses, and pembrolizumab, which reactivates cancer-fighti…

This phase III trial tested two different schedules of the chemotherapy drug paclitaxel (weekly vs. every three weeks) combined with carboplatin, with or without the targeted drug bevacizumab, in 692 patients with advanced ovarian, peritoneal, or fallopian tube cancer. The goal w…

This early-phase trial tests the safety of combining two cancer drugs, nivolumab and cabozantinib, in people with HIV who have advanced solid tumors. Only 8 participants were enrolled. The goal is to see if the combination is safe and can shrink or stabilize tumors.

This phase 2 trial tests a treatment called LN-145, made from a patient's own immune cells taken from their tumor. These cells are grown in a lab and then given back to the patient to attack the cancer. The study includes people with ovarian cancer, triple-negative breast cancer,…

This study tests whether adding heated chemotherapy directly into the abdomen during surgery can help people with relapsed ovarian cancer live longer. About 415 adults whose cancer returned in the abdomen after initial treatment will take part. The approach aims to control the di…

This early-phase trial tests the safety and best dose of two drugs, APG-1252 and cobimetinib, given together to people whose ovarian or endometrial cancer has come back. The drugs work by blocking proteins that help cancer cells survive and grow. The goal is to see if the combina…

This study tests a drug called mirvetuximab soravtansine in people with a specific type of recurrent ovarian cancer that has high levels of a protein called folate receptor alpha. The drug delivers chemotherapy directly to cancer cells to try to slow or stop the cancer from growi…

This early-phase trial tests two oral cancer drugs, niraparib and neratinib, given together. The first part aims to find the safest dose in people with advanced solid tumors. The second part checks if that dose can keep platinum-resistant ovarian cancer from growing for at least …

This study tests whether adding a gene therapy called IMNN-001 to standard chemotherapy can help people with advanced ovarian, fallopian tube, or peritoneal cancer live longer without their cancer growing. About 130 newly diagnosed patients will receive either the combination or …

This early-phase trial tests a new approach for ovarian cancer that has stopped responding to platinum chemotherapy. It combines TILT-123, a virus engineered to kill cancer cells and boost immune activity, with the immunotherapy drug pembrolizumab, and in some cases also with a c…

This study tests a new drug called PF-07104091 in people with advanced small cell lung cancer, ovarian cancer, or certain breast cancers that have not responded to prior treatments. The goal is to find the safest dose and see if the drug shrinks tumors, either alone or with other…

This study was designed to test the safety and effectiveness of two drugs, bemarituzumab and bevacizumab, given together to people with advanced gynecologic cancers (endometrial, ovarian, or cervical) that have a specific protein called FGFR2b. The trial was withdrawn before enro…

This pilot study tests whether adding zoledronic acid (a bone-strengthening drug) to standard chemotherapy and a targeted therapy can help women with ovarian cancer that no longer responds to platinum-based treatment. The study involves 14 participants and focuses on measuring im…

This study tests whether combining two immunotherapy drugs, ONC-392 and pembrolizumab, can shrink tumors in people with platinum-resistant ovarian cancer. About 58 adults with high-grade serous ovarian, primary peritoneal, or fallopian tube cancer are taking part. The goal is to …

This study tests whether adding heated chemotherapy directly into the abdomen during surgery helps people with stage III ovarian cancer live longer. About 538 participants will be randomly assigned to standard surgery alone or surgery plus the heated chemo. The main goal is to se…

This early-phase trial tests a new approach for people with ovarian, fallopian tube, or peritoneal cancer that has returned or not responded to standard treatments. Patients receive their own T cells, which are genetically modified to recognize and attack cancer cells, along with…

This trial tests a new drug combination for women with recurrent ovarian cancer that has come back after initial treatment. The study includes 54 participants and uses an antibody called oregovomab along with standard chemotherapy and bevacizumab. The goal is to see if this mix i…

This early-phase trial tests a new immune cell therapy called FT536 for people with recurrent ovarian, fallopian tube, or primary peritoneal cancer. The treatment is given directly into the abdomen after a short course of chemotherapy. Only 3 participants are enrolled, so the mai…

This study aimed to test new cancer drugs, alone or in combination, for people with advanced or recurrent ovarian cancer. The treatments were chosen based on specific genetic markers in each person's tumor. However, the study was withdrawn before enrolling any participants, so no…

This phase 2 trial is testing whether adding oregovomab (an antibody) to niraparib (a daily pill) can better control platinum-sensitive recurrent ovarian cancer. Ten women whose cancer came back after initial chemotherapy will receive both drugs for 12 weeks. The main goal is to …

This phase 2 trial tests whether pembrolizumab (Keytruda) can shrink or control advanced solid tumors that have certain gene mutations (BRCA1, BRCA2, POLE, POLD1). The study enrolled 21 adults with cancers that have spread or come back. Researchers measure how many patients see t…

This study tested a combination of three drugs—nivolumab, bevacizumab, and rucaparib—in 72 people whose ovarian, fallopian tube, or peritoneal cancer had returned after standard treatment. The goal was to see if the drugs could shrink tumors or slow the cancer's growth. While som…

This phase 2 trial tests whether adding an experimental antibody called oregovomab to standard chemotherapy (paclitaxel and carboplatin) helps control advanced ovarian, fallopian tube, or peritoneal cancer better than chemo alone. About 88 women with newly diagnosed stage III or …

This Phase 3 trial tests whether adding an experimental antibody called oregovomab to standard chemotherapy (paclitaxel and carboplatin) helps people with newly diagnosed advanced ovarian cancer live longer without their cancer getting worse. About 615 participants who had surger…

This study tests whether the hormone therapy letrozole alone works as well as chemotherapy (paclitaxel and carboplatin) followed by letrozole for people with stage II-IV low-grade serous ovarian, fallopian tube, or peritoneal cancer. About 450 participants will be randomly assign…

This phase 3 trial tests whether giving heated chemotherapy directly into the abdomen during surgery can help people with advanced ovarian cancer live longer without the disease coming back. About 362 participants will either receive standard surgery alone or surgery plus the hea…

This study tests a drug called BGB-290 (Pamiparib) as a maintenance treatment for people with recurrent ovarian cancer whose tumors shrank or disappeared after platinum-based chemotherapy. The goal is to see if taking this drug daily can delay the cancer from coming back. The tri…

This study tests a new drug called NP-G2-044 (Prilukae) combined with standard chemotherapy (PLD) in people with ovarian cancer that no longer responds to platinum-based treatments. About 380 participants will receive either the combo or PLD alone to see if the combination improv…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (paclitaxel, with or without bevacizumab) can slow the growth of ovarian cancer that has become resistant to platinum-based treatments. About 643 adults with recurrent ovarian, fallopian…

This early-phase trial tests whether giving heated chemotherapy directly into the abdomen during surgery can help prevent cancer from coming back in people with advanced ovarian, fallopian tube, uterine, or peritoneal cancer. About 40 participants will receive the heated chemo du…

This study tests a drug called sacituzumab govitecan in 20 people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The drug works like a guided missile, delivering chemotherapy directly to cancer cells. The mai…

This phase 2 trial tests whether a combination of three drugs—olaparib, durvalumab, and a cancer vaccine called UV1—can help keep ovarian cancer from coming back after chemotherapy. The study includes 188 patients with recurrent ovarian cancer who do not have BRCA mutations. Part…

This study looks at whether removing the fallopian tubes at the same time as a hysterectomy (for non-cancer reasons) can lower the chance of getting ovarian cancer later. About 4,400 women under 55 will be randomly assigned to have their tubes removed or not. Researchers will tra…

This study tests a new treatment for women whose ovarian cancer has come back. It combines chemotherapy and immunotherapy given directly into the abdomen with a drug given through a vein. The goal is to see if this approach can shrink or eliminate tumors. The study involves 24 pa…

This study tests whether a combination of surgery to remove visible tumors plus heated chemotherapy delivered directly into the abdomen can help people with ovarian cancer that has stopped responding to standard platinum-based chemo. About 140 adults with this type of recurrent o…

This study tests a new combination of three FDA-approved drugs (lenvatinib, pembrolizumab, and paclitaxel) in women whose endometrial, ovarian, fallopian tube, or primary peritoneal cancer has returned after prior treatment. The goal is to see if the triple therapy shrinks tumors…

This phase 3 study tests a drug called IMP4297 (a PARP inhibitor) as a maintenance treatment for people with advanced ovarian cancer (stage III or IV) who have finished their first round of chemotherapy. The goal is to see if taking this drug daily can delay the cancer from comin…

This study tests a new drug, NUV-1511, in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the drug can shrink tumors in cancers like breast, prostate, pancreatic, and ovarian cancer. About 466 adults will ta…

This study was designed to test a new drug called BAT8006 in people with ovarian cancer that no longer responds to platinum-based chemotherapy. The drug works by targeting a protein on cancer cells to deliver a toxic payload directly. However, the study was withdrawn before any p…

This early-stage trial is testing a new drug called KFA115, either by itself or combined with the immunotherapy Keytruda (pembrolizumab), in 126 people with advanced cancers like lung, skin, kidney, and others. The main goal is to check safety and find the best dose. It is not ye…

This study tests whether adding two newer drugs (dostarlimab and niraparib) to standard chemotherapy helps people with advanced ovarian cancer live longer without their cancer growing. About 1,400 participants with stage III or IV ovarian cancer will receive either the standard t…

This study looked at adding the drug bevacizumab to standard chemotherapy (carboplatin and paclitaxel or gemcitabine) and surgery for people with ovarian, peritoneal, or fallopian tube cancer that came back after initial treatment. Over 1,000 participants were randomly assigned t…

This early-phase study tests a new treatment for women with recurrent epithelial ovarian cancer. The therapy uses the patient's own immune cells, modified to find and attack cancer cells that carry a protein called B7-H3. The main goal is to check safety and find the best dose, w…

This phase 3 trial tests whether taking olaparib tablets daily can delay the return of advanced ovarian cancer in women with BRCA gene mutations. Participants had already responded to initial platinum chemotherapy. The study compares olaparib to a placebo over up to two years, me…

This early-stage study tests a new drug called BL-M17D1 in 120 adults with advanced solid tumors that have HER2 protein or gene changes. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Participants must have tried at least one standard…

This study tests a two-step treatment for a type of ovarian cancer that has come back after initial chemotherapy. First, patients receive a standard chemo drug (carboplatin) plus a targeted drug (mirvetuximab) that homes in on a protein called FRα found on cancer cells. Then, the…

This study looks at the best time to perform surgery for advanced ovarian cancer. It compares having surgery right away versus after a few rounds of chemotherapy. The goal is to see which approach helps people live longer. About 800 women with stage IIIB-IV ovarian cancer are tak…

This phase 2 study tests whether combining the immunotherapy drug pembrolizumab (Keytruda) with an experimental vaccine called DPX-Survivac and low-dose chemotherapy (cyclophosphamide) can shrink tumors in people with advanced ovarian, peritoneal, or fallopian tube cancer. The va…

This early-phase study is testing a new radioactive tracer called [18F]FTT to see how it moves through the body and how well it lights up ovarian, fallopian tube, or peritoneal cancer on PET scans. Up to 40 women with known or suspected cancer will join two imaging groups. The go…

This early-phase trial explores whether two experimental PET/CT tracers, 68Ga-FAPI-46 and 68Ga-PSMA-11, can accurately highlight various non-prostate cancers, including breast, lung, and pancreatic tumors. Participants scheduled for surgery will receive the tracers before their s…

This phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…

This study was designed to see if a blood test called the ROMA score could find ovarian cancer coming back sooner than the usual CA125 test. The goal was to catch recurrences early, which might allow less invasive surgery and improve quality of life. However, the study was withdr…

This study compares two types of imaging scans—PET/MR and contrast-enhanced CT (CECT)—to see which one better locates ovarian cancer tumors in the abdomen. Researchers aim to find out if PET/MR can more accurately predict whether tumors can be fully removed during surgery and how…

This study tests different programs to help people at high risk for cancer (such as those with BRCA or Lynch syndrome) or cancer survivors increase their physical activity and eat healthier. The goal is to see which programs work best to reduce cancer risk. About 337 participants…

This study looks at whether eating a diet high in magnesium can help prevent low blood magnesium levels in women with ovarian cancer who are receiving carboplatin chemotherapy. Low magnesium is a common side effect of this treatment. The study enrolled 26 participants and will me…

This early-stage study tests an experimental vaccine designed to prevent cancer in adults with BRCA1 or BRCA2 gene mutations. The vaccine is given alone or with another drug, followed by a mild electric pulse to help it enter cells. Researchers want to see if it is safe and wheth…

This study looks at three approaches to prevent ovarian cancer in women with BRCA1 or BRCA2 gene mutations: regular screening, removing both fallopian tubes and ovaries at once, or removing only the fallopian tubes first and the ovaries later. The two-step surgery aims to delay m…

This study tests a program of exercise, protein drinks, and mind-body activities like yoga for people aged 65 and older with advanced ovarian or pancreatic cancer. The goal is to see if patients can stick with the program while on chemotherapy before surgery. The study is small, …

This Phase 3 trial tests a drug called M701, given as an injection into the belly, to see if it can reduce the need for draining fluid in people with malignant ascites from advanced stomach, colorectal, or ovarian cancer. About 312 participants will either receive M701 plus drain…

This study tests a workshop called HOPE designed to reduce feelings of hopelessness and helplessness in patients with recurrent ovarian cancer. Sixty participants will either attend the workshop or receive usual care. Researchers will measure whether the workshop is feasible, acc…

This pilot study tests whether a supplement called AHCC, made from cultured mushroom mycelia, can improve quality of life for ovarian cancer patients receiving standard chemotherapy. About 20 participants will take either AHCC or a placebo during their treatment. The main goal is…

This study tests whether using a special monitor (ANI) during ovarian cancer surgery to guide pain medicine can lower the chance of chronic pain three months after the operation. About 126 women having open surgery for ovarian cancer will be randomly assigned to standard care or …

This study tests an online program called Day by Day for women with stage III or IV gynecologic cancer who have high fear of their cancer getting worse or coming back. The program teaches skills to manage anxiety and reframe worries. About 23 women will try the program for 12 wee…

This pilot study tests whether a personalized home exercise program is practical and helpful for women with advanced ovarian cancer who are receiving chemotherapy before surgery. Twenty-two participants will follow daily exercises and weekly coaching until their operation. The ma…

This study tests a web-based education tool called HOPE-Genomics that teaches cancer patients about their genetic test results. About 465 adults with breast, colorectal, lung, ovarian, pancreatic, or prostate cancer are taking part. The goal is to see if the tool helps patients r…

This phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …

This pilot study aims to see if doctors can consistently measure paclitaxel levels in the blood of cancer patients receiving the drug. The goal is to eventually adjust doses to give enough chemo to fight cancer while reducing the common side effect of nerve damage. The study invo…

This study enrolled over 78,000 women to see if regular screening with ultrasound and blood tests can lower the number of deaths from ovarian cancer. Participants were randomly assigned to either receive screening or usual care. The goal is to find out if catching the cancer earl…

This study follows 750 women with advanced ovarian cancer in Germany to see how they are treated in real-world settings. It focuses on the use of PARP inhibitor maintenance therapy after chemotherapy and how it affects outcomes and quality of life. The goal is to learn what works…

This study investigates whether certain blood-based markers, such as the neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and the CA-125 elimination rate (KELIM score), can predict survival and surgical outcomes in women with advanced ovarian cancer. Researcher…

This phase 2 trial is testing how the immunotherapy drug pembrolizumab (Keytruda) changes immune-related genes and biomarkers in people with advanced solid tumors like head and neck cancer, triple-negative breast cancer, ovarian cancer, and melanoma. Researchers will analyze bloo…

This study aims to find out why some cancer patients develop nerve damage (tingling or numbness in hands and feet) from taxane chemotherapy. Researchers will track over 1,300 people with breast, lung, or ovarian cancer to see how age, gender, and other factors affect their risk. …

This study is a long-term follow-up for 400 people who previously received A2 Bio gene therapy for various solid tumors, including colorectal, lung, pancreatic, and ovarian cancers. No new treatment is given; instead, researchers will track participants over time to check for del…

This study looks at whether offering genetic testing to family members of people with hereditary breast and ovarian cancer syndrome helps more relatives learn about their own cancer risk. Researchers will follow 118 participants and their relatives to see how many choose to get t…

This study collects tissue and blood samples from 1,600 people with various advanced cancers, along with their medical information, over the course of their treatment. Researchers will store these samples and data in a biobank for current and future studies. The goal is to better…

This study tests whether thin slices of ovarian tumors, kept alive in the lab, can predict how a patient will respond to chemotherapy. Researchers will take tumor samples from 48 women with advanced ovarian cancer during surgery. They will then expose the slices to different drug…

This early-phase trial is testing a drug called adavosertib in 38 people with advanced ovarian, fallopian tube, or peritoneal cancer. Participants take the drug for up to 28 days before their scheduled surgery. Researchers will compare tumor DNA before and after treatment to see …

This study looks at how a person's genes and medical history might help predict nerve damage caused by chemotherapy. Researchers will follow 300 people with certain cancers who are scheduled for specific chemo drugs. The goal is to find patterns that could help prevent or reduce …

This study looks at people with advanced ovarian cancer who have a second look laparoscopy after finishing their first chemotherapy. Doctors want to compare health outcomes between those who still have small amounts of cancer left and those who don't. They also want to see if thi…

This study uses artificial intelligence to analyze data from over 1,000 people with advanced ovarian cancer. The goal is to create a tool that helps doctors decide whether to perform surgery right away or after chemotherapy. The research combines information from a previous clini…

This trial was designed to test whether an online mental health program could help women with advanced gynecologic or breast cancer manage their fear of the cancer returning or getting worse. The study planned to compare the online program to standard educational materials. Howev…

This study follows 100 women with breast or gynecologic cancers to see if their diet before chemotherapy is linked to levels of a protein called hepcidin, and whether hepcidin levels affect how much chemo they can receive. The goal is to understand if eating certain foods might h…